
    
      This study includes 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion). In phase
      1, patients were enrolled using 3+3 dose escalation design. The starting dose of ARQ 531 in
      oral tablet form was 5mg/day continuously. The RP2D has been determined at 65mg/day, patients
      will be enrolled to one of 8 cohorts depending on tumor histology and prior treatment
      history. Cycle length will be 28 days.
    
  